30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more13th September 2019
Researchers are calling for population-wide BRCA testing in the Jewish community after finding it to be more effective than current approaches, cost effective and to have a high satisfaction rate with those undergoing testing.
Read more4th July 2019
Dr Oliver Pearce has received a Cancer Research UK Career Establishment Award, which will fund a project that will look at restoring response to immunotherapy in triple-negative breast cancer.
Read more4th June 2019
Professor Peter Schmid, Lead of the Centre for Experimental Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London, attended this year’s ASCO Annual Meeting and today presented updated survival data from the IMpassion130 trial.
Read more5th March 2019
Dr Ranjit Manchanda from Barts Cancer Institute, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts Health NHS Trust, was announced today as one of 13 Fellows to join the NHS […]
Read more19th November 2018
Centrosomal amplification, a particular change that occurs within some cancer cells, has been shown to drive the invasion of neighbouring cancer cells.
Read more